PAG
TCRR

Private Advisor Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Private Advisor Group’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-33,631
Closed -$93K – 2279
2022
Q1 		$93K Buy
33,631
+22,608
+205% +$71.1K ﹤0.01% 1999
2021
Q4 		$52K Buy
+11,023
New +$68.9K ﹤0.01% 2074

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Private Advisor Group's TCRR Position: Q2 2022 in Review

Private Advisor Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 33,631 shares — an estimated $93K sold.

Private Advisor Group first reported a position in TCRR in Q4 2021 and held it in 2 quarters. The position peaked at $93K in Q1 2022. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Private Advisor Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Private Advisor Group sold 33,631 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $93K.
  • Private Advisor Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Private Advisor Group's TCR2 Therapeutics Inc. Common Stock position peaked at $93K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on Private Advisor Group's 13F filing for Q2 2022, filed 13 Jul 2022.